Skip to main content

Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.

Publication ,  Journal Article
Karady, J; McGarrah, RW; Nguyen, M; Giamberardino, SN; Meyersohn, N; Lu, MT; Staziaki, PV; Puchner, SB; Bittner, DO; Foldyna, B; Mayrhofer, T ...
Published in: Am J Prev Cardiol
June 2024

OBJECTIVES: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. METHODS: Individuals with available CT data and blood samples enrolled in the PROMISE trial were studied. HS was defined based on CT attenuation. Lipoprotein particle size/number were measured by nuclear magnetic resonance spectroscopy. Principal components analysis (PCA) was used for dimensionality reduction. The association of PCA factors and individual lipoprotein particle size/number with HS were assessed in multivariable regression models. Associations were validated in an independent cohort of 59 individuals with histopathology defined HS. RESULTS: Individuals with HS (n=410/1,509) vs those without (n=1,099/1,509), were younger (59±8 vs 61±8 years) and less often females (47.6 % vs 55.9 %). All PCA factors were associated with HS: factor 1 (OR:1.36, 95 %CI:1.21-1.53), factor 3 (OR:1.75, 95 %CI:1.53-2.02) and factor 4 (OR:1.49; 95 %CI:1.32-1.68) were weighted heavily with small low density lipoprotein (LDL) and triglyceride-rich (TRL) particles, while factor 2 (OR:0.86, 95 %CI:0.77-0.97) and factor 5 (OR:0.74, 95 %CI:0.65-0.84) were heavily loaded with high density lipoprotein (HDL) and larger LDL particles. These observations were confirmed with the analysis of individual lipoprotein particles in PROMISE. In the validation cohort, association between HS and large TRL (OR: 8.16, 95 %CI:1.82-61.98), and mean sizes of TRL- (OR: 2.82, 95 %CI:1.14-9.29) and HDL (OR:0.35, 95 %CI:0.13-0.72) were confirmed. CONCLUSIONS: Large TRL, mean sizes of TRL-, and HDL were associated with radiographic and histopathologic HS. The use of lipoprotein particle size/number could improve cardiovascular risk assessment in HS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Prev Cardiol

DOI

EISSN

2666-6677

Publication Date

June 2024

Volume

18

Start / End Page

100680

Location

Netherlands

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karady, J., McGarrah, R. W., Nguyen, M., Giamberardino, S. N., Meyersohn, N., Lu, M. T., … Ferencik, M. (2024). Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial. Am J Prev Cardiol, 18, 100680. https://doi.org/10.1016/j.ajpc.2024.100680
Karady, Julia, Robert W. McGarrah, Maggie Nguyen, Stephanie N. Giamberardino, Nandini Meyersohn, Michael T. Lu, Pedro V. Staziaki, et al. “Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.Am J Prev Cardiol 18 (June 2024): 100680. https://doi.org/10.1016/j.ajpc.2024.100680.
Karady, Julia, et al. “Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.Am J Prev Cardiol, vol. 18, June 2024, p. 100680. Pubmed, doi:10.1016/j.ajpc.2024.100680.
Karady J, McGarrah RW, Nguyen M, Giamberardino SN, Meyersohn N, Lu MT, Staziaki PV, Puchner SB, Bittner DO, Foldyna B, Mayrhofer T, Connelly MA, Tchernof A, White PJ, Nasir K, Corey K, Voora D, Pagidipati N, Ginsburg GS, Kraus WE, Hoffmann U, Douglas PS, Shah SH, Ferencik M. Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial. Am J Prev Cardiol. 2024 Jun;18:100680.

Published In

Am J Prev Cardiol

DOI

EISSN

2666-6677

Publication Date

June 2024

Volume

18

Start / End Page

100680

Location

Netherlands

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology